会议报道

订阅

MedSci主页 / 所有栏目 / 会议报道

随机、双盲双模拟、平行对照、多中心评价埃克替尼和吉非替尼治疗既往接受过一个或两个化疗的局部晚期或转移的非小细胞肺癌患者的疗效和安全性III 期临床研究

2010-09-19 MedSci原创 MedSci原创

孙燕肺癌研究
关注

　　报告者：中国医学科学院肿瘤医院孙燕  　　时间：9 月17 日09:30～09:50  　　地点：16 区1 层大宴会厅 　　盐酸埃克替尼是一种口服表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI），属国家Ⅰ类新药，化学结构上和吉非替尼及厄洛替尼相似。本研究主要目的为比较埃克替尼与吉非替尼治疗晚期非小细胞肺癌（NSCLC）患者

　　报告者：中国医学科学院肿瘤医院孙燕 

　　时间：9 月17 日09:30～09:50 

　　地点：16 区1 层大宴会厅

　　盐酸埃克替尼是一种口服表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI），属国家Ⅰ类新药，化学结构上和吉非替尼及厄洛替尼相似。本研究主要目的为比较埃克替尼与吉非替尼治疗晚期非小细胞肺癌（NSCLC）患者的无进展生存期（PFS），次要终点包括总生存期、总体客观肿瘤缓解率（ORR）、疾病控制率、至疾病进展时间（TTP）、肺癌症状和健康相关的生活质量、安全性。 

　　研究对象为既往接受过一至两个化疗方案，局部晚期或转移的NSCLC ⅢB/Ⅳ期疾病进展的患者，研究组及对照组各200例。本研究于2010年4月中旬已达到方案规定的至少75%的受试者观察到终点事件的试验终结点。第一次揭盲已完成。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1990501, encodeId=2137199050120, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Jun 01 09:52:00 CST 2011, time=2011-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775244, encodeId=a6591e7524497, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Fri Sep 02 06:52:00 CST 2011, time=2011-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720791, encodeId=dffd1e2079185, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Fri Jul 15 21:52:00 CST 2011, time=2011-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059398, encodeId=7f40205939809, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sat Feb 05 17:52:00 CST 2011, time=2011-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650693, encodeId=d5ff165069388, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47614, encryptionId=ffae4e614b6, topicName=局部晚期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=901d24099859, createdName=yhy100208, createdTime=Thu Jan 20 20:52:00 CST 2011, time=2011-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915749, encodeId=0b4c1915e49cd, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Apr 30 23:52:00 CST 2011, time=2011-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903884, encodeId=eb031903884b9, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sun Oct 17 12:52:00 CST 2010, time=2010-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405615, encodeId=39dd140561523, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Tue Sep 21 10:52:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444043, encodeId=e99614440436c, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Tue Sep 21 10:52:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455534, encodeId=53ae14555348e, content=<a href='/topic/show?id=011941548ad' target=_blank style='color:#2F92EE;'>#埃克替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41548, encryptionId=011941548ad, topicName=埃克替尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0275676034, createdName=zhzhxiang, createdTime=Tue Sep 21 10:52:00 CST 2010, time=2010-09-21, status=1, ipAttribution=)]
    2011-06-01 gds2009

    #肺癌患者#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1990501, encodeId=2137199050120, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Jun 01 09:52:00 CST 2011, time=2011-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775244, encodeId=a6591e7524497, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Fri Sep 02 06:52:00 CST 2011, time=2011-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720791, encodeId=dffd1e2079185, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Fri Jul 15 21:52:00 CST 2011, time=2011-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059398, encodeId=7f40205939809, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sat Feb 05 17:52:00 CST 2011, time=2011-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650693, encodeId=d5ff165069388, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47614, encryptionId=ffae4e614b6, topicName=局部晚期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=901d24099859, createdName=yhy100208, createdTime=Thu Jan 20 20:52:00 CST 2011, time=2011-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915749, encodeId=0b4c1915e49cd, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Apr 30 23:52:00 CST 2011, time=2011-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903884, encodeId=eb031903884b9, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sun Oct 17 12:52:00 CST 2010, time=2010-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405615, encodeId=39dd140561523, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Tue Sep 21 10:52:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444043, encodeId=e99614440436c, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Tue Sep 21 10:52:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455534, encodeId=53ae14555348e, content=<a href='/topic/show?id=011941548ad' target=_blank style='color:#2F92EE;'>#埃克替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41548, encryptionId=011941548ad, topicName=埃克替尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0275676034, createdName=zhzhxiang, createdTime=Tue Sep 21 10:52:00 CST 2010, time=2010-09-21, status=1, ipAttribution=)]
    2011-09-02 amyloid

    #对照#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1990501, encodeId=2137199050120, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Jun 01 09:52:00 CST 2011, time=2011-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775244, encodeId=a6591e7524497, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Fri Sep 02 06:52:00 CST 2011, time=2011-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720791, encodeId=dffd1e2079185, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Fri Jul 15 21:52:00 CST 2011, time=2011-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059398, encodeId=7f40205939809, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sat Feb 05 17:52:00 CST 2011, time=2011-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650693, encodeId=d5ff165069388, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47614, encryptionId=ffae4e614b6, topicName=局部晚期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=901d24099859, createdName=yhy100208, createdTime=Thu Jan 20 20:52:00 CST 2011, time=2011-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915749, encodeId=0b4c1915e49cd, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Apr 30 23:52:00 CST 2011, time=2011-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903884, encodeId=eb031903884b9, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sun Oct 17 12:52:00 CST 2010, time=2010-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405615, encodeId=39dd140561523, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Tue Sep 21 10:52:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444043, encodeId=e99614440436c, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Tue Sep 21 10:52:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455534, encodeId=53ae14555348e, content=<a href='/topic/show?id=011941548ad' target=_blank style='color:#2F92EE;'>#埃克替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41548, encryptionId=011941548ad, topicName=埃克替尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0275676034, createdName=zhzhxiang, createdTime=Tue Sep 21 10:52:00 CST 2010, time=2010-09-21, status=1, ipAttribution=)]
    2011-07-15 经常头晕

    #疗效和安全性#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1990501, encodeId=2137199050120, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Jun 01 09:52:00 CST 2011, time=2011-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775244, encodeId=a6591e7524497, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Fri Sep 02 06:52:00 CST 2011, time=2011-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720791, encodeId=dffd1e2079185, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Fri Jul 15 21:52:00 CST 2011, time=2011-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059398, encodeId=7f40205939809, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sat Feb 05 17:52:00 CST 2011, time=2011-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650693, encodeId=d5ff165069388, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47614, encryptionId=ffae4e614b6, topicName=局部晚期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=901d24099859, createdName=yhy100208, createdTime=Thu Jan 20 20:52:00 CST 2011, time=2011-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915749, encodeId=0b4c1915e49cd, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Apr 30 23:52:00 CST 2011, time=2011-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903884, encodeId=eb031903884b9, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sun Oct 17 12:52:00 CST 2010, time=2010-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405615, encodeId=39dd140561523, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Tue Sep 21 10:52:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444043, encodeId=e99614440436c, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Tue Sep 21 10:52:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455534, encodeId=53ae14555348e, content=<a href='/topic/show?id=011941548ad' target=_blank style='color:#2F92EE;'>#埃克替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41548, encryptionId=011941548ad, topicName=埃克替尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0275676034, createdName=zhzhxiang, createdTime=Tue Sep 21 10:52:00 CST 2010, time=2010-09-21, status=1, ipAttribution=)]
    2011-02-05 lingaifan

    #非小细胞#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1990501, encodeId=2137199050120, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Jun 01 09:52:00 CST 2011, time=2011-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775244, encodeId=a6591e7524497, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Fri Sep 02 06:52:00 CST 2011, time=2011-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720791, encodeId=dffd1e2079185, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Fri Jul 15 21:52:00 CST 2011, time=2011-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059398, encodeId=7f40205939809, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sat Feb 05 17:52:00 CST 2011, time=2011-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650693, encodeId=d5ff165069388, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47614, encryptionId=ffae4e614b6, topicName=局部晚期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=901d24099859, createdName=yhy100208, createdTime=Thu Jan 20 20:52:00 CST 2011, time=2011-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915749, encodeId=0b4c1915e49cd, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Apr 30 23:52:00 CST 2011, time=2011-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903884, encodeId=eb031903884b9, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sun Oct 17 12:52:00 CST 2010, time=2010-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405615, encodeId=39dd140561523, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Tue Sep 21 10:52:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444043, encodeId=e99614440436c, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Tue Sep 21 10:52:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455534, encodeId=53ae14555348e, content=<a href='/topic/show?id=011941548ad' target=_blank style='color:#2F92EE;'>#埃克替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41548, encryptionId=011941548ad, topicName=埃克替尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0275676034, createdName=zhzhxiang, createdTime=Tue Sep 21 10:52:00 CST 2010, time=2010-09-21, status=1, ipAttribution=)]
    2011-01-20 yhy100208

    #局部晚期#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1990501, encodeId=2137199050120, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Jun 01 09:52:00 CST 2011, time=2011-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775244, encodeId=a6591e7524497, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Fri Sep 02 06:52:00 CST 2011, time=2011-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720791, encodeId=dffd1e2079185, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Fri Jul 15 21:52:00 CST 2011, time=2011-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059398, encodeId=7f40205939809, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sat Feb 05 17:52:00 CST 2011, time=2011-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650693, encodeId=d5ff165069388, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47614, encryptionId=ffae4e614b6, topicName=局部晚期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=901d24099859, createdName=yhy100208, createdTime=Thu Jan 20 20:52:00 CST 2011, time=2011-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915749, encodeId=0b4c1915e49cd, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Apr 30 23:52:00 CST 2011, time=2011-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903884, encodeId=eb031903884b9, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sun Oct 17 12:52:00 CST 2010, time=2010-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405615, encodeId=39dd140561523, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Tue Sep 21 10:52:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444043, encodeId=e99614440436c, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Tue Sep 21 10:52:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455534, encodeId=53ae14555348e, content=<a href='/topic/show?id=011941548ad' target=_blank style='color:#2F92EE;'>#埃克替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41548, encryptionId=011941548ad, topicName=埃克替尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0275676034, createdName=zhzhxiang, createdTime=Tue Sep 21 10:52:00 CST 2010, time=2010-09-21, status=1, ipAttribution=)]
    2011-04-30 juliusluan78

    #III#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1990501, encodeId=2137199050120, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Jun 01 09:52:00 CST 2011, time=2011-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775244, encodeId=a6591e7524497, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Fri Sep 02 06:52:00 CST 2011, time=2011-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720791, encodeId=dffd1e2079185, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Fri Jul 15 21:52:00 CST 2011, time=2011-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059398, encodeId=7f40205939809, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sat Feb 05 17:52:00 CST 2011, time=2011-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650693, encodeId=d5ff165069388, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47614, encryptionId=ffae4e614b6, topicName=局部晚期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=901d24099859, createdName=yhy100208, createdTime=Thu Jan 20 20:52:00 CST 2011, time=2011-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915749, encodeId=0b4c1915e49cd, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Apr 30 23:52:00 CST 2011, time=2011-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903884, encodeId=eb031903884b9, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sun Oct 17 12:52:00 CST 2010, time=2010-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405615, encodeId=39dd140561523, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Tue Sep 21 10:52:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444043, encodeId=e99614440436c, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Tue Sep 21 10:52:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455534, encodeId=53ae14555348e, content=<a href='/topic/show?id=011941548ad' target=_blank style='color:#2F92EE;'>#埃克替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41548, encryptionId=011941548ad, topicName=埃克替尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0275676034, createdName=zhzhxiang, createdTime=Tue Sep 21 10:52:00 CST 2010, time=2010-09-21, status=1, ipAttribution=)]
    2010-10-17 luoxiaog

    #多中心#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1990501, encodeId=2137199050120, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Jun 01 09:52:00 CST 2011, time=2011-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775244, encodeId=a6591e7524497, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Fri Sep 02 06:52:00 CST 2011, time=2011-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720791, encodeId=dffd1e2079185, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Fri Jul 15 21:52:00 CST 2011, time=2011-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059398, encodeId=7f40205939809, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sat Feb 05 17:52:00 CST 2011, time=2011-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650693, encodeId=d5ff165069388, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47614, encryptionId=ffae4e614b6, topicName=局部晚期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=901d24099859, createdName=yhy100208, createdTime=Thu Jan 20 20:52:00 CST 2011, time=2011-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915749, encodeId=0b4c1915e49cd, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Apr 30 23:52:00 CST 2011, time=2011-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903884, encodeId=eb031903884b9, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sun Oct 17 12:52:00 CST 2010, time=2010-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405615, encodeId=39dd140561523, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Tue Sep 21 10:52:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444043, encodeId=e99614440436c, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Tue Sep 21 10:52:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455534, encodeId=53ae14555348e, content=<a href='/topic/show?id=011941548ad' target=_blank style='color:#2F92EE;'>#埃克替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41548, encryptionId=011941548ad, topicName=埃克替尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0275676034, createdName=zhzhxiang, createdTime=Tue Sep 21 10:52:00 CST 2010, time=2010-09-21, status=1, ipAttribution=)]
    2010-09-21 chg122

    #局部#

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1990501, encodeId=2137199050120, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Jun 01 09:52:00 CST 2011, time=2011-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775244, encodeId=a6591e7524497, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Fri Sep 02 06:52:00 CST 2011, time=2011-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720791, encodeId=dffd1e2079185, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Fri Jul 15 21:52:00 CST 2011, time=2011-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059398, encodeId=7f40205939809, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sat Feb 05 17:52:00 CST 2011, time=2011-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650693, encodeId=d5ff165069388, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47614, encryptionId=ffae4e614b6, topicName=局部晚期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=901d24099859, createdName=yhy100208, createdTime=Thu Jan 20 20:52:00 CST 2011, time=2011-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915749, encodeId=0b4c1915e49cd, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Apr 30 23:52:00 CST 2011, time=2011-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903884, encodeId=eb031903884b9, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sun Oct 17 12:52:00 CST 2010, time=2010-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405615, encodeId=39dd140561523, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Tue Sep 21 10:52:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444043, encodeId=e99614440436c, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Tue Sep 21 10:52:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455534, encodeId=53ae14555348e, content=<a href='/topic/show?id=011941548ad' target=_blank style='color:#2F92EE;'>#埃克替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41548, encryptionId=011941548ad, topicName=埃克替尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0275676034, createdName=zhzhxiang, createdTime=Tue Sep 21 10:52:00 CST 2010, time=2010-09-21, status=1, ipAttribution=)]
    2010-09-21 huagfeg

    #评价#

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1990501, encodeId=2137199050120, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Jun 01 09:52:00 CST 2011, time=2011-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775244, encodeId=a6591e7524497, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Fri Sep 02 06:52:00 CST 2011, time=2011-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720791, encodeId=dffd1e2079185, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Fri Jul 15 21:52:00 CST 2011, time=2011-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059398, encodeId=7f40205939809, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sat Feb 05 17:52:00 CST 2011, time=2011-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650693, encodeId=d5ff165069388, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47614, encryptionId=ffae4e614b6, topicName=局部晚期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=901d24099859, createdName=yhy100208, createdTime=Thu Jan 20 20:52:00 CST 2011, time=2011-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915749, encodeId=0b4c1915e49cd, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Apr 30 23:52:00 CST 2011, time=2011-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903884, encodeId=eb031903884b9, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sun Oct 17 12:52:00 CST 2010, time=2010-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405615, encodeId=39dd140561523, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Tue Sep 21 10:52:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444043, encodeId=e99614440436c, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Tue Sep 21 10:52:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455534, encodeId=53ae14555348e, content=<a href='/topic/show?id=011941548ad' target=_blank style='color:#2F92EE;'>#埃克替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41548, encryptionId=011941548ad, topicName=埃克替尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0275676034, createdName=zhzhxiang, createdTime=Tue Sep 21 10:52:00 CST 2010, time=2010-09-21, status=1, ipAttribution=)]
    2010-09-21 zhzhxiang

    #埃克替尼#

    0

以上为热门评论，梅斯医学App还有更多内容